THE AstraZeneca Covid-19 vaccine (ChAdOx1-S [Recombinant]) was effective at preventing Covid-19 infections due to Omicron when used as a fourth dose booster, according to new data from Thailand's Chiang Mai University.
In the real-word evidence study, AstraZeneca showed vaccine effectiveness (VE) of 73 percent (95 percent confidence interval [CI] 48 percent to 89 percent) against the highly transmissible Omicron variant when a fourth dose was given on top of any previous primary or booster vaccine. According to the study authors, these were the first known data assessing the effectiveness of a mixed (heterologous) four-dose Covid-19 vaccine schedule.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.